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Background: Zygomatic implants can provide excellent remote anchorage to sup-
port the prosthetic rehabilitation of patients treated for maxillary and midfacial
tumors.
Methods: Patients who underwent zygomatic implant placement by the author
between 2006 and 2016 as part of their oncology treatment were followed
prospectively.
Results: Forty-nine consecutively treated patients received 131 zygomatic implants
of which 9 failed and were removed from 4 patients; 24 patients (49%) received
radiotherapy either before or after implant insertion. The overall 12-month survival
estimate was 94% and the 60-month estimate was 92%.
Conclusions: The use of zygomatic implants in the management of maxillary and
midfacial malignancy is a predictable prosthetic treatment modality to support
complex oral and facial prostheses. Their use with or without free tissue transfer
can provide effective prosthetic rehabilitation with high implant survival irrespec-
tive of the timing of placement or the need for adjuvant radiotherapy.
Clinical Significance: Zygomatic Implants provide an excellent platform for the
restoration of the dentition and facial structures affected by maxillary and midfacial
malignant disease.
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1 | INTRODUCTION
Malignant diseases of the maxilla and midface, although rel-
atively rare, require radical and often combined treatment
modalities to affect cure for the patient. The location, nature,
and size of the primary tumor dictate the margins of the re-
section and the potential functional and cosmetic effect that
the patient will subsequently have. Functional problems for
such patients are all too common due to the central location
of the maxilla and midface with potential for significant dis-
turbance for speech, swallowing, and chewing as well as
dental and facial appearance. The use of classifications such
as those by Brown1 and Okay2 are helpful tools to assist
with surgical planning and decision-making regarding surgi-
cal reconstruction, prosthetic obturation, and dental rehabili-
tation in this very complex area, but there are a wide variety
of treatment approaches reported in the literature. The use of
microvascular free tissue transfer has significantly advanced
the management of this patient group, especially for larger
tumors (Brown class III/IV) with a greater vertical compo-
nent, which have the ability to significantly impact the facial
appearance and/or require orbital enucleation. Although the
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use of composite flaps in the maxillectomy patient has been
well reported,3,4 there is still much debate about the best flap
to use in a specific circumstance, and this often comes down
to patient fitness as well as the preference and experience of
the surgical team. The use of composite flaps can provide
much needed bony support for cosmetic facial support5 and
also provide bone for subsequent or immediate osseointe-
grated implant insertion to facilitate dental rehabilitation.6
The subsequent provision of a dental prosthesis in these
high-level maxillectomy cases, although possible, is often not
provided due to the difficulties in tolerating a conventional
dental prosthesis after such surgeries, lack of prosthodontic
expertise or funding for dental implants, or lack of patient
suitability with the result that very few patients ultimately
receive an implant-based rehabilitation.7 When any type of
prosthesis is required in this group of patients, the use of
osseointegrated implants provide a much-needed foundation
for its retention, stability, and overall patient acceptance. The
use of conventional osseointegrated implants in maxillectomy
patients have been reported for the support of oral and facial
prostheses for some years,8 and in recent years the use of
zygomatic implants have been gaining more acceptance in the
management of patients with complex maxillary and midface
tumors.9,10
The use of conventional zygomatic implants inserted in a
horizontal manner across the face to support nasal prostheses
was first described by Bowden11 and has subsequently been
more widely adopted with reports of larger case series9 dem-
onstrating high survival and predictability with a low com-
plication rate. Figure 1 demonstrates the use of this
technique in a patient requiring total rhinectomy for an intra-
nasal squamous cell carcinoma. The use of zygomatic
implants to support maxillary obturator or fixed dental pros-
theses are more limited, with mainly case reports12–16 being
presented involving the secondary placement on patients
with maxillary defects with a varying survival rates being
reported (from 79% to 100%). The most significant report to
date is by Boyes-Varley et al.17 who presented a protocol
using modified zygomatic (Oncology) implants specifically
developed by a South African Implant company (Southern
Implants Ltd, South Africa) for use in maxillary defect situa-
tions (Figure 2). The implant used had a roughened thread
length of approximately 20 mm with the rest of the implant
surface being polished to minimize the attachment of debris
and maximize cleaning when used in oncology defect situa-
tions. Their protocol involved the primary placement of
oncology implants on the maxillary defect side together with
the placement of modified dental or standard zygomatic
implants on the nondefect side with the subsequent provision
of an early-loaded fixed dental prosthesis and separate
acrylic palatal obturator prosthesis within 1-2 weeks of sur-
gery. They reported the successful treatment of 20 patients
FIGURE 1 The use of horizontally placed zygomatic implants to support a bar-magnet-retained nasal prosthesis in a patient requiring total rhinectomy for
malignant disease [Color figure can be viewed at wileyonlinelibrary.com]
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with no reported loss of the oncology zygomatic implants.
Certainly, the use of zygomatic oncology implants placed at
the time of primary surgery offers significant benefits to the
retention and support of obturator prostheses, and their use
has also been documented by the author in a pediatric patient
more recently18 (Figure 3).
In an attempt to maximize the benefit to patients and to
reduce the burden of hygiene and prosthetic maintenance,
the treatment paradigm for low-level maxillary malignancy
has continued to advance to encompass fixed dental rehabili-
tation together with the use of microvascular soft tissue flap
closure. The zygomatic implant perforated flap procedure19
combines the advantages of autogenous soft tissue recon-
struction with those of an early-loaded zygomatic implant-
supported fixed dental prosthesis (Figure 4), which can be
delivered in the first 4-6 weeks after surgery irrespective of
the subsequent need for radiotherapy.
The placement of osseointegrated dental implants at the
time of primary cancer surgery is certainly gaining popularity
across many centers20,21 as the potential for more rapid reha-
bilitation is a clear advantage together with the avoidance of
subsequent surgical trauma in the event that the patient
requires radiotherapy for disease control. However, with
respect to the timing of zygomatic implant placement in oncol-
ogy patients, there is no comparative published data to assess
the performance and survival of zygomatic implants placed
either at the time of surgery or at a later point in the patient's
cancer journey. This study attempts to address these questions.
2 | MATERIALS AND METHODS
The use of zygomatic and modified zygomatic (oncology)
implants placed between 2006 and 2016 was studied in the
Department of Maxillofacial Surgery, Aintree University
Hospital, Liverpool, UK, and the Liverpool University
Dental Hospital. Institutional approval was gained for data
collection to facilitate the evaluation of the zygomatic
implant service for patients with head and neck cancer. The
aims of the study were to evaluate the survival of these
implants utilized in the prosthetic rehabilitation of patients
with maxillary and midface tumors and to ascertain whether
the timing of placement had any bearing on zygomatic
FIGURE 2 Zygomatic oncology implant; note the polished portion of the
implant designed to allow use in maxillary or facial defects
FIGURE 3 The use of oncology zygomatic implants in the support of a maxillary obturator prosthesis [Color figure can be viewed at
wileyonlinelibrary.com]
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implant usability or survival. All patients treated by the
author with conventional or oncology zygomatic implants
during the study period were included in the analysis.
Patients were followed regularly during the study period to
monitor their overall disease control as well as any issues
with their implants and prostheses. When patients died with
their implants and prosthesis intact, their date of death was
taken as the final data point for implant survival and prosthe-
sis follow-up. The University of Washington Quality of Life
(UW-QOL) questionnaire was sent out to many of the
patients in this cohort as part of our routine quality of life
data collection within the center. A further posting was car-
ried out to long-term survivors at the end of the study period
to gain a long-term picture of the outcome of these treat-
ments. When multiple questionnaires had been completed by
the patient, the latest questionnaire was used for the QOL
analysis. Version 4 of the UW-QOL questionnaire consists
of 12 single-question domains; these have between 3 and
6 response options that are scaled according to the hierarchy
of the response. The domains are pain, appearance, activity,
recreation, swallowing, chewing, speech, shoulder, taste,
saliva, mood, and anxiety. Another question asks patients to
choose up to three domains that have been the most impor-
tant to them. In regard to their overall QOL (six response
options), patients are asked to consider not only physical and
mental health but also many other factors, such as family,
friends, spirituality, or personal leisure activities, that were
important to their enjoyment of life. The whole question-
naire focuses on current patient health and quality of life
within the past 7 days. By comparing UW-QOL responses
with responses to more in-depth questionnaires collected at
the same time, algorithm trigger cutoffs have been derived22
that define a “significant problem” on each UW-QOL
domain. It is also informative to know the other extreme,
that is, those giving the best possible response. Logically,
there is middle ground between these extremes, and by creat-
ing three categories we present a simple summary of varia-
tion within each domain.
2.1 | Statistical method
Kaplan-Meier curves were constructed for the survival time
of implants to failure and then separately for conventional
zygomatic vs oncology implants and for primary vs second-
ary implants. These require the assumption of independence
of each implant in regard to failure. Cox regression was used
to make these comparisons after adjusting for clustering
within patients. A separate patient-level Kaplan-Meier analy-
sis was made of the time to (first) failure.
3 | RESULTS
During the study period, 53 patients with head and neck can-
cer were treated with 140 zygomatic and/or zygomatic oncol-
ogy implants as part of their oral and/or facial prosthetic
rehabilitation. Implants were placed either at the time of initial
resective surgery or at a secondary time point after successful
oncological treatment. Of the initial patient cohort, four
patients subsequently died of their disease without completing
their prosthetic rehabilitation. These patients and their 9 zygo-
matic implants were excluded from the study leaving a study
cohort of 49 patients and 131 zygomatic implants. The
FIGURE 4 Zygomatic implant perforated flap procedure for the management of a low-level maxillary tumor [Color figure can be viewed at
wileyonlinelibrary.com]
4 BUTTERWORTH
majority of the patients (35/49) had been diagnosed with
squamous cell carcinoma within the maxilla/midface. The
other patients were seen mainly with a number of other less-
common malignant tumors although one patient with a previ-
ous maxillary ameloblastoma, two patients with pleomorphic
salivary adenoma, and one patient suffering with maxillary
osteoradionecrosis were also included (Table 1).
The patients were divided into two main groups (primary
implant group [n = 27 patients] vs secondary implant group
[n = 22 patients]) depending on the timing of zygomatic
implant placement. The two groups were comparable in
terms of age, gender, and smoking status (Table 2). The sec-
ondary implant group was disadvantaged in terms of preop-
erative irradiation with eight patients (36%) having been
irradiated before implant placement. However, 15 patients
(56%) of the primary implant group subsequently received
radiotherapy following their resective surgery and implant
placement with radiotherapy usually commencing about
6 weeks postoperatively. In total, 24 of the 49 patients in the
study (49%) received radiotherapy either before or after
implant insertion.
The primary implant group received 75 zygomatic
implants of which 39 were of the oncology subtype, whereas
the secondary group received a total of 56 zygomatic
implants of which 19 were of the oncology subtype. In both
groups, a small number of additional standard dental
implants were used in the support of the final prosthesis for
some patients (primary group, n = 14 implants; secondary
group, n = 16 implants). The majority of implants were
loaded in a conventional manner after osseointegration had
taken place with the primary group having a tendency for
earlier loading (median 1.7 months [interquartile ratio
{IQR}, 0.9-3.9] months vs 9.3 [IQR, 5.2-12.2] months) due
to the introduction of earlier loading protocols within the
later years of the study. The zygomatic implants were subse-
quently used to retain and support a different range of oral
and facial prostheses including maxillary obturators, fixed
dental prostheses, maxillary overdentures, and facial pros-
theses (Table 3). All patients were followed up on a regular
basis with the overall surgical follow-up ranging from 2 to
110 months.
Nine zygomatic implants (three conventional and six
oncology) were removed from four patients, six within
4 months of placement, another two by 1 year and another
after 3 years of function. Implant survival was examined
using Kaplan-Meier calculations (Figures 5–7), and these
suggest 5-year survival rates of 90% or better, with slightly
better results for conventional zygomatic implants and for
primary implants emerging within the first couple of years.
The overall 12-month survival estimate was 94% and the
60-month estimate was 92%. However, the failure data
implies some clustering within patients of which Figures 5–7
do not allow for. Cox regression methods were used to
compare the type of implant (zygomatic vs oncology) and
timing (secondary vs primary) with respect to survival time
of the implant, after adjusting for clustering of implantation
within patient. The hazard ratios (HR) obtained suggested a
doubling (HR = 2.25) of risk of failure with secondary tim-
ing relative to primary and for a halving (HR = 0.56) for
zygomatic conventional implants relative to oncology
implants. Two methods (robust and bootstrap) of estimating
standard errors (SE) after adjusting for clustering gave dif-
ferent but large estimates, but neither of these HR results
achieved statistical significance (P ≥ 0.42). A separate
patient-level analysis (49 patients) was made of the time to
(first) failure with an overall 12-month survival estimate of
94% (SE, 4%) and a 60-month estimate of 90% (SE, 5%).
TABLE 1 Patient diagnoses (n = 49 patients)
Patient diagnoses Number of patients
SCC 35










Abbreviations: ORN, Osteoradionecrosis; SCC, squamous cell carcinoma.




Number of patients 27 (13 male; 14 female) 22 (12 male; 10 female)
Age, median (range), y 70 (13-92) 68 (23-79)
Smokers 14 (52%) 10 (45%)
Radiotherapy: postop 15 (56%) 1 (5%)
Radiotherapy: preop 0 8 (36%)





Conventional zygomatic implants 36 37
Oncology implants 39 19
Additional dental implants 14 (oral) 3 (nasion) 16 (oral)
Median time till loading (IQR), mo 1.7 (0.9-3.9) 9.3 (5.2-12.2)
Prostheses
Facial prosthesis 13 2
Obturator 10 10
Fixed dental prosthesis 4 7
Overdenture 2 3
Median prosthetic follow-up (IQR), mo 21.6 (12.4-39.9) 44.9 (29.0-68.9)
Median surgical follow-up, mo 42.7 (IQR 21.7-66.4; overall
range 2-110)
Abbreviation: IQR, interquartile range.
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The four (first) failures occurred at 2.9, 3.1, 3.9, and
38 months after surgery.
There were no significant postoperative surgical compli-
cations in the primary implant group; but in the secondary
implant group, two patients experienced a short-lived epi-
sode of infection in the skin overlying the zygomatic body
within 6 months of placement which subsequently resolved.
A further two patients developed chronic infections some
years after placement: one associated with bone loss around
the apex of an oncology implant used to support a removable
obturator and the other associated with a horizontally placed
implant to support a nasal prosthesis in a previously irradi-
ated patient. Both patients continue to function with limited
symptoms, and the associated implants remain in function to
date. Prosthodontic complications were also limited to a
small number of patients who experienced episodes of screw
loosening and screw fracture, with one particular patient
who was treated early in the study requiring significant pros-
thodontic maintenance, partly because the patient's large
obturator prosthesis was retained by only two zygomatic
implants and opposed by natural dentition in the mandible.
Twenty patients died during the course of the study
either of their disease or for other reasons. Of the patients
who died, their median postsurgical survival time was
23.8 months (IQR, 12.0-52.2 months), and their time with
their implant-retained prosthesis was 18.2 months (IQR,
9.8-44.9 months).
UW-QOL data were available for 51% (25/49) of the
patients. A summary of responses to the single question
domains is shown in Table 4, and these responses were a
median (IQR) of 35 (16-54) months after the fit of the pros-
thesis. Most patients (60%) were able to swallow as well as
ever, and none had significant problems in regard to swallow-
ing; most (72%), however, did recognize a change in appear-
ance although only one patient had a significant problem with
this. In regard to the overall QOL, 72% (18) said it was
“good,” “very good,” or “outstanding” (2 “outstanding,”
7 “very good,” 9 “good,” 6 “fair”, 1 “poor”, 0 “very poor”).
4 | DISCUSSION
The use of zygomatic implants to assist in the prosthetic
rehabilitation of patients following resections of the maxilla
and midface provides another significant tool to the multidis-
ciplinary teams managing these most complex groups of
patients. Although the use of dental implants made tremen-
dous strides forward in the management of these patients,
zygomatic and modified zygomatic implants provide another
tier of advantages for clinicians providing oral and facial
FIGURE 5 Kaplan-Meier survival estimate of all zygomatic implants
placed. The numbers in parentheses show the number of failures between
the stated time points, eight failures within 20 months, one failure within
21-40 months, and no failures thereafter [Color figure can be viewed at
wileyonlinelibrary.com]
FIGURE 6 Kaplan-Meier survival estimate comparing zygomatic vs
oncology implants. The numbers in parentheses show the number of failures
between the stated time points [Color figure can be viewed at
wileyonlinelibrary.com]
FIGURE 7 Kaplan-Meier survival estimate comparing primarily vs
secondarily placed zygomatic implants. The numbers in parentheses show
the number of failures between the stated time points [Color figure can be
viewed at wileyonlinelibrary.com]
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rehabilitation in the cancer setting. Insertion of these long
implants into the highly cortical bone of the zygoma pro-
vides very high and predictable initial stability in a position
remote to the resection of the tumor. The high initial stability
promotes immediate and early prosthetic loading of these
implants, which can result in full implant-supported dental
and/or facial rehabilitation within a matter of weeks.19 This
is highly desirable for any patient but especially in this
cohort of patients with cancer whose survival may be limited
or even reduced compared to other oral tumor sites.23 In
addition, rapid secure prosthodontic rehabilitation provides
much needed facial and lip support, especially in the edentu-
lous patient, as well as improving overall facial and dental
appearance, facilitating restoration of speech, and allowing a
faster return to social interactions and overall recovery.
Patient-reported quality-of-life outcomes in this study appear
to be favorable, with the majority of surviving patients
reporting an overall quality of life several years after treat-
ment as good, very good, or outstanding. In addition, the
number of patients reporting a significant dysfunction with
chewing, swallowing, speech, and appearance was extremely
low indeed. The literature on quality-of-life outcomes for
patients with head and neck cancer treated with zygomatic
implants is very sparse indeed although a recent paper
by Wang24 suggested that patients receiving an implant-
supported obturator had comparable quality of life and func-
tion to a patient provided with a fixed dental bridge
supported by implants in a vascularized bony reconstruction.
Certainly, the use of osseointegrated implants provides
much needed stability for dental and facial prostheses, and
clinically patient acceptance is much higher.
The “remote anchorage” concept is invaluable to pros-
thetic restoration in the maxillectomy situation with the api-
cal end of the implant providing the necessary mechanical
anchorage into the residual facial skeleton, the body of the
implant traversing through the space previously occupied by
the resected maxilla, and the angled head design allowing
subsequent prosthetic restoration (see Figure 3). When used
to support maxillary obturator prostheses, the use of zygo-
matic implants provides much needed “in-defect” support
and retention, which is impossible to achieve through stan-
dard dental implant-retained restorations. In-defect support
allows the patient to function on the defect side of the obtu-
rator prosthesis and prevents the prosthesis from being dis-
placed superiorly into the maxillectomy cavity, which is a
real problem for conventional obturator prostheses. The
oncology zygomatic implant provides the added advantage
of a polished midsection for such circumstances, and this is
designed to improve the patient's ability to clean the
implants as they emerge into the defect.
The placement of zygomatic implants requires a careful
three-dimensional awareness on the part of the surgeon to
ensure that the head of the implant is in a suitable position to
support the prosthesis while being firmly anchored within
the bone of the zygoma. Ideally, two implants should be
placed on the resected side if at all possible, and this
TABLE 4 Quality-of-life analysis of treated patients
UW-QOL domain
Number of







Pain 25 I have no pain 60% (15) 28% (7) 12% (3)
Appearance 25 There is no change in my appearance 28% (7) 68% (17) 4% (1)
Activity 25 I am as active as I have ever been 32% (8) 60% (15) 8% (2)
Recreation 25 There are no limitations to recreation at home or away from home 28% (7) 64% (16) 8% (2)
Swallowing 25 I can swallow as well as ever 60% (15) 40% (10) 0% (0)
Chewing 25 I can chew as well as ever 48% (12) 52% (13) 0% (0)
Speech 25 My speech is the same as always 40% (10) 52% (13) 8% (2)
Shoulder 25 I have no problem with my shoulder 60% (15) 32% (8) 8% (2)
Taste 25 I can taste food normally 48% (12) 36% (9) 16% (4)
Saliva 25 My saliva is of normal consistency 52% (13) 40% (10) 8% (2)
Mood 25 My mood is excellent and unaffected by my cancer 32% (8) 60% (15) 8% (2)
Anxiety 25 I am not anxious about my cancer 60% (15) 28% (7) 12% (3)
Abbreviation: UW-QOL, University of Washington Quality of Life.
FIGURE 8 3D surgical simulation of the placement of remotely anchored
zygomatic implants into the left residual zygoma following a previous left
low-level maxillectomy [Color figure can be viewed at
wileyonlinelibrary.com]
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provides technical challenges to the inexperienced surgeon
and may affect survival and usability. Figure 8 illustrates the
approximate trajectory and spacing required in the placement
of two remotely anchored zygomatic implants into a patient
following a previous low-level maxillectomy. The angle of
insertion is flatter than the contralateral native maxilla, and
the heads should be angulated slightly anteriorly to provide
adequate access postoperatively depending on the patient's
mouth opening and planned restoration.
Certainly, the zygomatic implant survival rates in
patients with cancer reported in the literature to date tend to
show worse results in general than those reported in the nor-
mal population, especially when secondary placement was
undertaken. In many respects, this is understandable when
the challenges of treating these cases are fully understood
and when only a small number of patients have been man-
aged in a single unit. The effects of smoking, radiotherapy,
and significant cantilevering forces must also be considered
as negative predictors as they are in patients receiving con-
ventional dental implant treatment. The current study brings
together a long-term view on the management of maxillary
and midfacial tumor patients treated with zygomatic and
modified zygomatic oncology implants. It demonstrates high
implant survival rates and confirms that this type of treat-
ment can be applied safely and effectively in the overall
prosthetic management of this patient group. It has been
shown that, even in a range of complex circumstances, zygo-
matic implants can be satisfactorily placed to always allow
their effective use in supporting a subsequent prosthesis. The
advantages of primary placement of osseointegrated
implants in patients with head and neck cancer are increas-
ingly being realized, and this study confirms that this
approach in the maxilla and midface provides the highest
survival rate and reduces the overall time to rehabilitation,
even when postoperative radiotherapy is required. In fact,
this study demonstrated primary zygomatic implant survival
rates only slightly lower to those reported in the manage-
ment of non-cancer patients.25 Certainly, access for zygo-
matic implant placement is much improved at primary
resective surgery, and this approach, in the view of the
author, should be the gold standard in the management of
patients requiring implant-based prosthetic rehabilitation for
malignant disease of the maxilla and midface together with
early prosthesis construction.
There was a nonsignificant trend towards worse implant
survival outcomes for patients treated secondarily rather than
primarily at the time of tumor resection, and this is in line
with what has been reported already in the literature. In addi-
tion, there was a trend for higher failure rates for zygomatic
oncology implants used for remote anchorage compared to
conventionally placed zygomatic implants. The use of Cox
regression analyses to look for significance in any of these
findings is frustrated by the nine implant failures clustering
within only four patients. This may be a relatively large
sample of patients with head and neck cancer, and the small
number of failures is good news clinically. However, from
the statistical perspective, the small number of failures
inhibits the precision of any analysis. The only pragmatic
way to confirm these potential observations would be a mul-
ticenter collaborative study. This study, however, does go a
long way to provide long-term data regarding the successful
use of zygomatic implants in patients with maxillary and
midfacial malignant disease.
5 | CONCLUSIONS
The use of zygomatic implants in the prosthetic management
of the patient with head and neck cancer provide excellent
remote anchorage for the support and retention of oral and
facial prostheses with high patient acceptance and resulting
quality-of-life outcomes. They demonstrated high survival
and usability even in highly complex situations where radio-
therapy was used in the postsurgical phase of the patient's
oncology treatment. There was a trend towards improved
survival when implants were placed at the time of primary
surgery compared to at a later date although this was not sta-
tistically significant in this large study.
6 | CLINICAL SIGNIFICANCE
The use of zygomatic and modified zygomatic implants pro-
vides predictable support and retention for complex oral and
facial prostheses for patients being treated for head and neck
cancer. High levels of implant survival are achievable even
in a cohort of patients subjected to radiotherapy as part of
disease control measures.
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